130 related articles for article (PubMed ID: 26865311)
1. A simplified approach for molecular classification of glioblastomas (GBMs): experience from a tertiary care center in India.
Purkait S; Mallick S; Sharma V; Kumar A; Pathak P; Jha P; Biswas A; Julka PK; Gupta D; Suri A; Upadhyay AD; Suri V; Sharma MC; Sarkar C
Brain Tumor Pathol; 2016 Jul; 33(3):183-90. PubMed ID: 26865311
[TBL] [Abstract][Full Text] [Related]
2. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.
Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C
Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Verhaak RG; Hoadley KA; Purdom E; Wang V; Qi Y; Wilkerson MD; Miller CR; Ding L; Golub T; Mesirov JP; Alexe G; Lawrence M; O'Kelly M; Tamayo P; Weir BA; Gabriel S; Winckler W; Gupta S; Jakkula L; Feiler HS; Hodgson JG; James CD; Sarkaria JN; Brennan C; Kahn A; Spellman PT; Wilson RK; Speed TP; Gray JW; Meyerson M; Getz G; Perou CM; Hayes DN;
Cancer Cell; 2010 Jan; 17(1):98-110. PubMed ID: 20129251
[TBL] [Abstract][Full Text] [Related]
5. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
6. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
7. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification of diffuse gliomas.
Jakovlevs A; Vanags A; Gardovskis J; Strumfa I
Pol J Pathol; 2019; 70(4):246-258. PubMed ID: 32146793
[TBL] [Abstract][Full Text] [Related]
11. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
[TBL] [Abstract][Full Text] [Related]
12. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
13. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
14. GBM-associated mutations and altered protein expression are more common in young patients.
Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
Chaurasia A; Park SH; Seo JW; Park CK
J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India.
Purkait S; Mallick S; Sharma V; Kumar A; Pathak P; Jha P; Biswas A; Julka PK; Gupta D; Suri A; Datt Upadhyay A; Suri V; Sharma MC; Sarkar C
Transl Oncol; 2016 Aug; 9(4):371-6. PubMed ID: 27567961
[TBL] [Abstract][Full Text] [Related]
17. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
18. A simplified approach for the molecular classification of glioblastomas.
Le Mercier M; Hastir D; Moles Lopez X; De Nève N; Maris C; Trepant AL; Rorive S; Decaestecker C; Salmon I
PLoS One; 2012; 7(9):e45475. PubMed ID: 23029035
[TBL] [Abstract][Full Text] [Related]
19. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
20. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]